Vimarsana
Biggest News Aggregation in the World

Page 43 - Ir Team News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ir Team Today - Breaking & Trending Today

ChipMOS Technologies Ltd (IMOS) Q4 2020 Earnings Call Transcript - Vimarsana News

ChipMOS Technologies Ltd (IMOS) Q4 2020 Earnings Call Transcript

Operator Greetings, and welcome to the ChipMOS Fourth Quarter and Full Year 2020 Results Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. I would now like to turn the conference over to Dr. G.S. Shen of ChipMOS Technologies Strategy and Investor Relations team to introduce the management team of the Company in Conference. Dr. Shen, you may begin. G.S. Shen -- Deputy Director of Strategy and Investor Relations Thank you, operator. Welcome everyone to ChipMOS' fourth quarter and full year 2020 results conference call. Joining us today ...

Source: fool.com
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients - Vimarsana News

Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients

Share this article Share this article SUZHOU, China, March 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale. In the clinical trial, Proxalutamide met the primary endpoint at day 14, demonstrating a reduction of 4.01 in WHO COVID-19 ordinal scale from a baseline of 5.663 to 1.653 in theÂ...

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma - Vimarsana News

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma

(1) - BLA submitted with FDA's breakthrough therapy designation - SHANGHAI, China and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. ("Coherus", Nasdaq: CHRS) announced today the initiation of the rolling submission of the Biologics License Application ("BLA") for toripalimab to the U.S. Food and Drug Administration ("FDA") for the treatment of recurrent or metastatic nasopharyngeal carcinoma ("NPC"). A rolling submission allows Junshi Biosciences to submit sections ...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China

Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China -- Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas -- Junshi will continue to be responsible for the promotion of other indications in core areas --The companies will continue to explore business collaborations in overseas markets including emerging markets SHANGHAI, China, March 01, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading inno...

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy - Vimarsana News

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy

Junshi Biosciences U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy SHANGHAI, China, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. government has agreed to purchase a minimum of 100,000 doses of etesevimab (JS016 or LY...